Kyowa Hakko Kirin (KHK) is a Japanese global Top 50 pharmaceutical company formed in 2008 by the merger of Kyowa Hakko and Kirin Pharma, and is a member of the Tokyo Stock Exchange Nikkei 225, the most widely quoted index of Japanese equities. With over US$5 billion in revenues in 2070 and a robust product pipeline, KHK is emerging as a major international player in the biotechnology and life science arena with particular strengths in oncology, nephrology, immunology and therapeutic antibody technologies.
展开▼
